arrow_back Back Filing freshness 10-Q Q3 FY2026 SEC EDGAR

Syndax Pharmaceuticals Inc

SNDX
$9.32 ▼ -1.15 (-10.94%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
49 Visible periods
27 Metrics
Peer-ranked Benchmarks
Price Chart
21
Health
Poor
Bearish
auto_awesome

Analytical Summary

Syndax Pharmaceuticals Inc faces fundamental challenges with weakness in Profit Margin (%) and Operating Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $836.8M
Dividend Yield —
Revenue Growth 81.6% ↘
Op. Margin -50.3% ↗
ROIC 192.6% ↗
FCF / Share $-0.30 ↗
Trailing P/E —
Price / Book —
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

49-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$83.30M
↑ +81.6% —
Net Income Profit after all expenses
$-42.67M
↑ +49.7% —
Operating Margin Operating profit as % of sales
-50.3%
↑ +8.5% 1th
FCF / Share Free cash flow per share
$-0.30
↑ +10.8% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability
1
Cash Quality →
70

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 13 years · 49 quarters